Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2010

01.11.2010 | Epidemiology

Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis

verfasst von: Patricia G. Moorman, Edwin S. Iversen, P. Kelly Marcom, Jeffrey R. Marks, Frances Wang, Eunjung Lee, Giske Ursin, Timothy R. Rebbeck, Susan M. Domchek, Banu Arun, Lisa Susswein, Claudine Isaacs, Judy E. Garber, Kala Visvanathan, Constance A. Griffin, Rebecca Sutphen, Jennifer Brzosowicz, Stephen Gruber, Dianne M. Finkelstein, Joellen M. Schildkraut, Kathleen Cuningham Consortium for Research into Familial Breast Cancer (kConFab)

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

The incomplete penetrance of mutations in BRCA1 and BRCA2 suggests that some combination of environmental and genetic factors modifies the risk of breast cancer in mutation carriers. This study sought to identify possible interactions between established breast cancer risk factors and BRCA1 or BRCA2 mutations using a case-only study design. Breast cancer cases that had been tested for BRCA1 and BRCA2 mutations were identified from 11 collaborating centers. Comparisons of reproductive and lifestyle risk factors were made between women with breast cancer who were positive for BRCA1 mutations (n = 283), BRCA2 mutations (n = 204), or negative for both BRCA1 and BRCA2 mutations (n = 894). Interaction risk ratios (IRRs) were calculated using multinominal logistic regression models. Compared with non-carriers, statistically significant IRRs were observed for later age at menarche among BRCA2 mutation carriers, for a greater number of pregnancies among both BRCA1 and BRCA2 mutation carriers, and for alcohol use among BRCA1 mutation carriers. Our data suggest that the risk for breast cancer among BRCA1 or BRCA2 carriers may be modified by reproductive characteristics and alcohol use. However, our results should be interpreted cautiously given the overall inconsistency in the epidemiologic literature on modifiers of BRCA1 and BRCA2.
Literatur
1.
Zurück zum Zitat Fackenthal JD, Olopade OI (2007) Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 7:937–948CrossRefPubMed Fackenthal JD, Olopade OI (2007) Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 7:937–948CrossRefPubMed
2.
Zurück zum Zitat Breast Cancer Linkage Consortium (1997) Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 349:1505–1510CrossRef Breast Cancer Linkage Consortium (1997) Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 349:1505–1510CrossRef
3.
Zurück zum Zitat Atchley DP, Albarracin CT, Lopez A et al (2008) Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 26:4282–4288CrossRefPubMed Atchley DP, Albarracin CT, Lopez A et al (2008) Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 26:4282–4288CrossRefPubMed
4.
Zurück zum Zitat Reis-Filho JS, Tutt AN (2008) Triple negative tumours: a critical review. Histopathology 52:108–118CrossRefPubMed Reis-Filho JS, Tutt AN (2008) Triple negative tumours: a critical review. Histopathology 52:108–118CrossRefPubMed
5.
Zurück zum Zitat Bordeleau L, Panchal S, Goodwin P (2010) Prognosis of BRCA-associated breast cancer: a summary of evidence. Breast Cancer Res Treat 119:13–24CrossRefPubMed Bordeleau L, Panchal S, Goodwin P (2010) Prognosis of BRCA-associated breast cancer: a summary of evidence. Breast Cancer Res Treat 119:13–24CrossRefPubMed
6.
Zurück zum Zitat Narod SA, Dube MP, Klijn J et al (2002) Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 94:1773–1779PubMed Narod SA, Dube MP, Klijn J et al (2002) Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 94:1773–1779PubMed
7.
Zurück zum Zitat Jernstrom H, Lerman C, Ghadirian P et al (1999) Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet 354:1846–1850CrossRefPubMed Jernstrom H, Lerman C, Ghadirian P et al (1999) Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet 354:1846–1850CrossRefPubMed
8.
Zurück zum Zitat Cullinane CA, Lubinski J, Neuhausen SL et al (2005) Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int J Cancer 117:988–991CrossRefPubMed Cullinane CA, Lubinski J, Neuhausen SL et al (2005) Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int J Cancer 117:988–991CrossRefPubMed
9.
Zurück zum Zitat Andrieu N, Goldgar DE, Easton DF et al (2006) Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). J Natl Cancer Inst 98:535–544CrossRefPubMed Andrieu N, Goldgar DE, Easton DF et al (2006) Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). J Natl Cancer Inst 98:535–544CrossRefPubMed
10.
Zurück zum Zitat Chang-Claude J, Andrieu N, Rookus M et al (2007) Age at menarche and menopause and breast cancer risk in the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev 16:740–746CrossRefPubMed Chang-Claude J, Andrieu N, Rookus M et al (2007) Age at menarche and menopause and breast cancer risk in the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev 16:740–746CrossRefPubMed
11.
Zurück zum Zitat Kotsopoulos J, Lubinski J, Lynch HT et al (2007) Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 105:221–228CrossRefPubMed Kotsopoulos J, Lubinski J, Lynch HT et al (2007) Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 105:221–228CrossRefPubMed
12.
Zurück zum Zitat McGuire V, John EM, Felberg A et al (2006) No increased risk of breast cancer associated with alcohol consumption among carriers of BRCA1 and BRCA2 mutations ages <50 years. Cancer Epidemiol Biomarkers Prev 15:1565–1567CrossRefPubMed McGuire V, John EM, Felberg A et al (2006) No increased risk of breast cancer associated with alcohol consumption among carriers of BRCA1 and BRCA2 mutations ages <50 years. Cancer Epidemiol Biomarkers Prev 15:1565–1567CrossRefPubMed
13.
Zurück zum Zitat Haile RW, Thomas DC, McGuire V et al (2006) BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. Cancer Epidemiol Biomarkers Prev 15:1863–1870CrossRefPubMed Haile RW, Thomas DC, McGuire V et al (2006) BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. Cancer Epidemiol Biomarkers Prev 15:1863–1870CrossRefPubMed
14.
Zurück zum Zitat Brohet RM, Goldgar DE, Easton DF et al (2007) Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. J Clin Oncol 25:3831–3836CrossRefPubMed Brohet RM, Goldgar DE, Easton DF et al (2007) Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. J Clin Oncol 25:3831–3836CrossRefPubMed
15.
Zurück zum Zitat Jernstrom H, Lubinski J, Lynch HT et al (2004) Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 96:1094–1098CrossRefPubMed Jernstrom H, Lubinski J, Lynch HT et al (2004) Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 96:1094–1098CrossRefPubMed
16.
Zurück zum Zitat Kotsopoulos J, Lubinski J, Lynch HT et al (2005) Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Causes Control 16:667–674CrossRefPubMed Kotsopoulos J, Lubinski J, Lynch HT et al (2005) Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Causes Control 16:667–674CrossRefPubMed
17.
Zurück zum Zitat Brunet JS, Ghadirian P, Rebbeck TR et al (1998) Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. J Natl Cancer Inst 90:761–766CrossRefPubMed Brunet JS, Ghadirian P, Rebbeck TR et al (1998) Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. J Natl Cancer Inst 90:761–766CrossRefPubMed
18.
Zurück zum Zitat Kotsopoulos J, Olopado OI, Ghadirian P et al (2005) Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res 7:R833–R843CrossRefPubMed Kotsopoulos J, Olopado OI, Ghadirian P et al (2005) Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res 7:R833–R843CrossRefPubMed
19.
Zurück zum Zitat Gronwald J, Byrski T, Huzarski T et al (2006) Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland. Breast Cancer Res Treat 95:105–109CrossRefPubMed Gronwald J, Byrski T, Huzarski T et al (2006) Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland. Breast Cancer Res Treat 95:105–109CrossRefPubMed
20.
Zurück zum Zitat Lee E, Ma H, McKean-Cowdin R et al (2008) Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study. Cancer Epidemiol Biomarkers Prev 17:3170–3178CrossRefPubMed Lee E, Ma H, McKean-Cowdin R et al (2008) Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study. Cancer Epidemiol Biomarkers Prev 17:3170–3178CrossRefPubMed
21.
Zurück zum Zitat Tryggvadottir L, Olafsdottir EJ, Gudlaugsdottir S et al (2003) BRCA2 mutation carriers, reproductive factors and breast cancer risk. Breast Cancer Res 5:R121–R128CrossRefPubMed Tryggvadottir L, Olafsdottir EJ, Gudlaugsdottir S et al (2003) BRCA2 mutation carriers, reproductive factors and breast cancer risk. Breast Cancer Res 5:R121–R128CrossRefPubMed
22.
Zurück zum Zitat Milne RL, Knight JA, John EM et al (2005) Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev 14:350–356CrossRefPubMed Milne RL, Knight JA, John EM et al (2005) Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev 14:350–356CrossRefPubMed
23.
Zurück zum Zitat Ursin G, Henderson BE, Haile RW et al (1997) Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women? Cancer Res 57:3678–3681PubMed Ursin G, Henderson BE, Haile RW et al (1997) Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women? Cancer Res 57:3678–3681PubMed
24.
Zurück zum Zitat Piegorsch WW, Weinberg CR, Taylor JA (1994) Non-hierarchical logistic models and case-only designs for assessing susceptibility in population-based case–control studies. Stat Med 13:153–162CrossRefPubMed Piegorsch WW, Weinberg CR, Taylor JA (1994) Non-hierarchical logistic models and case-only designs for assessing susceptibility in population-based case–control studies. Stat Med 13:153–162CrossRefPubMed
25.
Zurück zum Zitat Schmidt S, Schaid DJ (1999) Potential misinterpretation of the case-only study to assess gene–environment interaction. Am J Epidemiol 150:878–885PubMed Schmidt S, Schaid DJ (1999) Potential misinterpretation of the case-only study to assess gene–environment interaction. Am J Epidemiol 150:878–885PubMed
26.
Zurück zum Zitat Chen S, Parmigiani G (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25:1329–1333CrossRefPubMed Chen S, Parmigiani G (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25:1329–1333CrossRefPubMed
27.
Zurück zum Zitat Tai YC, Domchek S, Parmigiani G et al (2007) Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 99:1811–1814CrossRefPubMed Tai YC, Domchek S, Parmigiani G et al (2007) Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 99:1811–1814CrossRefPubMed
28.
Zurück zum Zitat Frank TS, Deffenbaugh AM, Reid JE et al (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10, 000 individuals. J Clin Oncol 20:1480–1490CrossRefPubMed Frank TS, Deffenbaugh AM, Reid JE et al (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10, 000 individuals. J Clin Oncol 20:1480–1490CrossRefPubMed
29.
Zurück zum Zitat Milne RL, Osorio A, Ramon y Cajal T et al (2009) Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 119:221–232CrossRefPubMed Milne RL, Osorio A, Ramon y Cajal T et al (2009) Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 119:221–232CrossRefPubMed
30.
Zurück zum Zitat Rebbeck TR, Wang Y, Kantoff PW et al (2001) Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. Cancer Res 61:5420–5424PubMed Rebbeck TR, Wang Y, Kantoff PW et al (2001) Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. Cancer Res 61:5420–5424PubMed
Metadaten
Titel
Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis
verfasst von
Patricia G. Moorman
Edwin S. Iversen
P. Kelly Marcom
Jeffrey R. Marks
Frances Wang
Eunjung Lee
Giske Ursin
Timothy R. Rebbeck
Susan M. Domchek
Banu Arun
Lisa Susswein
Claudine Isaacs
Judy E. Garber
Kala Visvanathan
Constance A. Griffin
Rebecca Sutphen
Jennifer Brzosowicz
Stephen Gruber
Dianne M. Finkelstein
Joellen M. Schildkraut
Kathleen Cuningham Consortium for Research into Familial Breast Cancer (kConFab)
Publikationsdatum
01.11.2010
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2010
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-010-0842-y

Weitere Artikel der Ausgabe 2/2010

Breast Cancer Research and Treatment 2/2010 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.